I'm not entirely familiar with the context of the statement. I'd prefer to provide a written answer.
In our experience, we do see that correlation between stronger intellectual property provisions and higher drug prices. It stands to reason that as you have only one manufacturer on the market, which is able to retain higher prices and no competition, the prices are going to remain high. In our experience, stronger IP protections do result in higher prices.